WHAT IS THE FUTURE OF USING OUTCOMES-BASED CONTRACTS BETWEEN PAYERS AND PHARMACEUTICAL MANUFACTURERS TO GAIN MARKET ACCESS FOR ADVANCED ONCOLOGIC AND BIOLOGIC AGENTS?

Author(s)

Paglia R1, Blackham J1, Del Carlo A1, Schwartz J1, Carter EA1, Foy C2, Dyson S2, Areteou T2
1Consulting at McCann Health, New York, NY, USA, 2Consulting at McCann Health, London, UK

OBJECTIVES: With the introduction of new oncologics, biologics, combination therapies, and advanced therapy medicinal products, global payers are managing costs by entering into risk arrangements with pharmaceutical manufacturers. Payers are limiting their financial risk/spending by adopting outcomes-based contracts (OBC) that link patient outcomes to payment for drug therapy. This research explores current and future trends for OBC, by market, along with barriers to implementation.

METHODS: This study used primary and secondary research. Subjects included 52 payers from US, Canada, France, Germany, Italy, Spain, and UK. Payers were defined as individuals who influenced coverage and reimbursement decisions made by health authorities or insurers. A literature search on payer utilization management in each market was conducted to gain insight and inform primary research, which consisted of online surveys and telephone interviews. All data and information were tabulated and analyzed.

RESULTS: OBC is being used to various degrees by global payers to manage risk/drug spend. In the US, 20 of 40 payers plan to start or expand use of OBC for expensive oncologics and biologics. The rationale included extracting maximum value out of expensive products based on real-world efficacy. Limitations included lack of harmonization of data from multiple sources. Ex-US countries were divided between those that more regularly employ OBC (UK, Italy and Canada) to manage drug spending, and those countries in which OBC are not regularly employed (France, Germany and Spain). Reasons for limited use of OBC include strict patient data protection regulations, the overall administrative burden of implementation, and the challenge of collecting patient data at the hospital level.

CONCLUSIONS: As the prices of new advanced therapies continue to rise, payers in selected markets will adopt or expand the use of OBC to manage spending. Pharmaceutical manufacturers need to develop innovative OBC strategies in conjunction with their clinical development plans.

Conference/Value in Health Info

2018-05, ISPOR 2018, Baltimore, MD, USA

Value in Health, Vol. 21, S1 (May 2018)

Code

PCN204

Topic

Economic Evaluation, Health Policy & Regulatory, Health Service Delivery & Process of Care, Health Technology Assessment

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Decision & Deliberative Processes, Formulary Development, Health Care Research, Hospital and Clinical Practices, Prescribing Behavior, Reimbursement & Access Policy

Disease

Musculoskeletal Disorders, Oncology, Rare and Orphan Diseases, Systemic Disorders/Conditions

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×